Novel ISCOMs from Quillaja brasiliensis saponins induce mucosal and systemic antibody production, T-cell responses and improved antigen uptake. Issue 9 (24th February 2016)

• Record Type: Journal Article
• Authors: Cibulski, Samuel Paulo; Mourglia-Ettlin, Gustavo; Teixeira, Thais Fumaco; Quirici, Lenora; Roehe, Paulo Michel; Ferreira, Fernando; Silveira, Fernando
• Is Part Of: Vaccine. Volume 34:Issue 9(2016)
• Page Start: 1162
• Page End: 1171
• Publication Date: 2016-02-24
• Subjects: Quillaja brasiliensis -- ISCOM -- Uptake -- Subcutaneously -- Intranasally delivered -- Humoral and cell responses; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2016.01.029
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: Novel ISCOMs formulated with Quillaja brasiliensis saponins. IQB90 were efficiently uptaken by murine bone marrow-derived dendritic cells. Subcutaneously inoculated IQB-90 induced strong serum antibody responses. Intranasally delivered IQB-90 elicited serum IgG and IgG1 and mucosal IgA. IQB-90 is a promising alternative to classic ISCOMs as vaccine adjuvants. Abstract: In the last decades, significant efforts have been dedicated to the search for novel vaccine adjuvants. In this regard, saponins and its formulations as "immunostimulating complexes" (ISCOMs) have shown to be capable of stimulating potent humoral and cellular immune responses, enhanced cytokine production and activation of cytotoxic T cells. The immunological activity of ISCOMs formulated with a saponin fraction extracted from Quillaja brasiliensis (QB-90 fraction) as an alternative to classical ISCOMs based on Quil A ® (IQA) is presented here. The ISCOMs prepared with QB-90, named IQB-90, typically consist of 40–50 nm, spherical, cage-like particles, built up by QB-90, cholesterol, phospholipids and antigen (ovalbumin, OVA). These nanoparticles were efficiently uptaken in vitro by murine bone marrow-derived dendritic cells. Subcutaneously inoculated IQB-90 induced strong serum antibody responses encompassing specific IgG1 and IgG2a, robust DTH reactions, significant T cell proliferation and increases in Th1 (IFN-γ and IL-2) cytokine responses. Intranasally delivered IQB-90 elicited serum IgG and IgG1, and mucosal IgA responses at distal systemic sites (nasal passages, large intestine and vaginal lumen). These results indicate that IQB-90 is a promising alternative to classic ISCOMs as vaccine adjuvants, capable of enhancing humoral and cellular immunity to levels comparable to those induced by ISCOMs manufactured with Quillaja saponaria saponins.